Humoral response to two doses of BNT162b2 vaccination in people with HIV

Line Dam Heftdal; Andreas Dehlbaek Knudsen; Sebastian Rask Hamm; Cecilie Bo Hansen; Dina Leth Møller; Mia Pries-Heje; Kamille Fogh; Rasmus Bo Hasselbalch; Ida Jarlhelt; Laura Pérez-Alós; Linda Maria Hilsted; Sisse Rye Ostrowski; Jan Gerstoft; Kirsten Grønbaek; Henning Bundgaard; Kasper Iversen; Peter Garred; Susanne Dam Nielsen

doi:10.1111/joim.13419

Humoral response to two doses of BNT162b2 vaccination in people with HIV

^*Corresponding author for this work

36 Citations (Scopus)

Abstract

BACKGROUND: People with HIV (PWH) are at increased risk of severe COVID-19. We aimed to determine humoral responses in PWH and controls who received two doses of BNT162b2.

METHODS: In 269 PWH and 538 age-matched controls, we measured IgG and neutralizing antibodies specific for the receptor-binding domain of SARS-CoV-2 at baseline, 3 weeks and 2 months after the first dose of BNT162b2.

RESULTS: IgG antibodies increased from baseline to 3 weeks and from 3 weeks to 2 months in both groups, but the concentrations of IgG antibodies were lower in PWH than that in controls at 3 weeks and 2 months (p = 0.025 and <0.001), respectively. The IgG titres in PWH with a humoral response at 2 months were 77.9% (95% confidence interval [62.5%-97.0%], age- and sex-adjusted p = 0.027) of controls.

CONCLUSIONS: Reduced IgG antibody response to vaccination with BNT162b2 was found in PWH, and thus increased awareness of breakthrough infections in PWH is needed.

Original language	English
Journal	Journal of Internal Medicine
Volume	291
Issue number	4
Pages (from-to)	513-518
Number of pages	6
ISSN	0954-6820
DOIs	https://doi.org/10.1111/joim.13419
Publication status	Published - Apr 2022

Keywords

antibody response
BNT162b2
HIV
SARS-CoV-2
vaccine

Access to Document

10.1111/joim.13419

Cite this

Heftdal, L. D., Knudsen, A. D., Hamm, S. R., Hansen, C. B., Møller, D. L., Pries-Heje, M., Fogh, K., Hasselbalch, R. B., Jarlhelt, I., Pérez-Alós, L., Hilsted, L. M., Ostrowski, S. R., Gerstoft, J., Grønbaek, K., Bundgaard, H., Iversen, K., Garred, P., & Nielsen, S. D. (2022). Humoral response to two doses of BNT162b2 vaccination in people with HIV. Journal of Internal Medicine, 291(4), 513-518. https://doi.org/10.1111/joim.13419

Heftdal, LD, Knudsen, AD , Hamm, SR , Hansen, CB , Møller, DL , Pries-Heje, M, Fogh, K, Hasselbalch, RB, Jarlhelt, I, Pérez-Alós, L, Hilsted, LM , Ostrowski, SR , Gerstoft, J , Grønbaek, K , Bundgaard, H , Iversen, K , Garred, P & Nielsen, SD 2022, 'Humoral response to two doses of BNT162b2 vaccination in people with HIV', Journal of Internal Medicine, vol. 291, no. 4, pp. 513-518. https://doi.org/10.1111/joim.13419

@article{382940ec5e734d68bf4765491da9a274,

title = "Humoral response to two doses of BNT162b2 vaccination in people with HIV",

abstract = "BACKGROUND: People with HIV (PWH) are at increased risk of severe COVID-19. We aimed to determine humoral responses in PWH and controls who received two doses of BNT162b2.METHODS: In 269 PWH and 538 age-matched controls, we measured IgG and neutralizing antibodies specific for the receptor-binding domain of SARS-CoV-2 at baseline, 3 weeks and 2 months after the first dose of BNT162b2.RESULTS: IgG antibodies increased from baseline to 3 weeks and from 3 weeks to 2 months in both groups, but the concentrations of IgG antibodies were lower in PWH than that in controls at 3 weeks and 2 months (p = 0.025 and <0.001), respectively. The IgG titres in PWH with a humoral response at 2 months were 77.9\% (95\% confidence interval [62.5\%-97.0\%], age- and sex-adjusted p = 0.027) of controls.CONCLUSIONS: Reduced IgG antibody response to vaccination with BNT162b2 was found in PWH, and thus increased awareness of breakthrough infections in PWH is needed.",

keywords = "antibody response, BNT162b2, HIV, SARS-CoV-2, vaccine",

author = "Heftdal, \{Line Dam\} and Knudsen, \{Andreas Dehlbaek\} and Hamm, \{Sebastian Rask\} and Hansen, \{Cecilie Bo\} and M{\o}ller, \{Dina Leth\} and Mia Pries-Heje and Kamille Fogh and Hasselbalch, \{Rasmus Bo\} and Ida Jarlhelt and Laura P{\'e}rez-Al{\'o}s and Hilsted, \{Linda Maria\} and Ostrowski, \{Sisse Rye\} and Jan Gerstoft and Kirsten Gr{\o}nbaek and Henning Bundgaard and Kasper Iversen and Peter Garred and Nielsen, \{Susanne Dam\}",

year = "2022",

month = apr,

doi = "10.1111/joim.13419",

language = "English",

volume = "291",

pages = "513--518",

journal = "Journal of Internal Medicine",

issn = "0954-6820",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Humoral response to two doses of BNT162b2 vaccination in people with HIV

AU - Heftdal, Line Dam

AU - Knudsen, Andreas Dehlbaek

AU - Hamm, Sebastian Rask

AU - Hansen, Cecilie Bo

AU - Møller, Dina Leth

AU - Pries-Heje, Mia

AU - Fogh, Kamille

AU - Hasselbalch, Rasmus Bo

AU - Jarlhelt, Ida

AU - Pérez-Alós, Laura

AU - Hilsted, Linda Maria

AU - Ostrowski, Sisse Rye

AU - Gerstoft, Jan

AU - Grønbaek, Kirsten

AU - Bundgaard, Henning

AU - Iversen, Kasper

AU - Garred, Peter

AU - Nielsen, Susanne Dam

PY - 2022/4

Y1 - 2022/4

N2 - BACKGROUND: People with HIV (PWH) are at increased risk of severe COVID-19. We aimed to determine humoral responses in PWH and controls who received two doses of BNT162b2.METHODS: In 269 PWH and 538 age-matched controls, we measured IgG and neutralizing antibodies specific for the receptor-binding domain of SARS-CoV-2 at baseline, 3 weeks and 2 months after the first dose of BNT162b2.RESULTS: IgG antibodies increased from baseline to 3 weeks and from 3 weeks to 2 months in both groups, but the concentrations of IgG antibodies were lower in PWH than that in controls at 3 weeks and 2 months (p = 0.025 and <0.001), respectively. The IgG titres in PWH with a humoral response at 2 months were 77.9% (95% confidence interval [62.5%-97.0%], age- and sex-adjusted p = 0.027) of controls.CONCLUSIONS: Reduced IgG antibody response to vaccination with BNT162b2 was found in PWH, and thus increased awareness of breakthrough infections in PWH is needed.

AB - BACKGROUND: People with HIV (PWH) are at increased risk of severe COVID-19. We aimed to determine humoral responses in PWH and controls who received two doses of BNT162b2.METHODS: In 269 PWH and 538 age-matched controls, we measured IgG and neutralizing antibodies specific for the receptor-binding domain of SARS-CoV-2 at baseline, 3 weeks and 2 months after the first dose of BNT162b2.RESULTS: IgG antibodies increased from baseline to 3 weeks and from 3 weeks to 2 months in both groups, but the concentrations of IgG antibodies were lower in PWH than that in controls at 3 weeks and 2 months (p = 0.025 and <0.001), respectively. The IgG titres in PWH with a humoral response at 2 months were 77.9% (95% confidence interval [62.5%-97.0%], age- and sex-adjusted p = 0.027) of controls.CONCLUSIONS: Reduced IgG antibody response to vaccination with BNT162b2 was found in PWH, and thus increased awareness of breakthrough infections in PWH is needed.

KW - antibody response

KW - BNT162b2

KW - HIV

KW - SARS-CoV-2

KW - vaccine

UR - https://www.scopus.com/pages/publications/85121385903

U2 - 10.1111/joim.13419

DO - 10.1111/joim.13419

M3 - Journal article

C2 - 34841629

SN - 0954-6820

VL - 291

SP - 513

EP - 518

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

IS - 4

ER -

Humoral response to two doses of BNT162b2 vaccination in people with HIV

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this